BNP Paribas Financial Markets Purchases 68,487 Shares of Alkermes plc (NASDAQ:ALKS)

BNP Paribas Financial Markets grew its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 45.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 217,980 shares of the company's stock after purchasing an additional 68,487 shares during the quarter. BNP Paribas Financial Markets owned about 0.13% of Alkermes worth $6,269,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Allostery Investments LP bought a new position in shares of Alkermes during the 4th quarter valued at $3,451,000. AdvisorShares Investments LLC raised its holdings in shares of Alkermes by 58.9% during the 4th quarter. AdvisorShares Investments LLC now owns 13,171 shares of the company's stock valued at $379,000 after purchasing an additional 4,881 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Alkermes by 9.6% during the 4th quarter. Northern Trust Corp now owns 1,912,132 shares of the company's stock valued at $54,993,000 after purchasing an additional 167,452 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Alkermes by 0.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 196,831 shares of the company's stock valued at $5,661,000 after purchasing an additional 1,088 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Alkermes during the 4th quarter valued at $492,000. Institutional investors own 95.21% of the company's stock.

Alkermes Stock Performance

Shares of NASDAQ:ALKS traded up $0.21 on Friday, hitting $31.42. 992,676 shares of the company were exchanged, compared to its average volume of 1,765,523. The company's 50 day moving average price is $30.56 and its two-hundred day moving average price is $30.74. Alkermes plc has a one year low of $22.90 and a one year high of $36.45. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of 14.48, a PEG ratio of 2.20 and a beta of 0.51.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The business had revenue of $306.51 million for the quarter, compared to analyst estimates of $307.53 million. During the same quarter last year, the firm posted $0.43 earnings per share. Alkermes's revenue was down 12.6% on a year-over-year basis. Research analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALKS has been the topic of a number of research analyst reports. StockNews.com lowered shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. HC Wainwright reiterated a "neutral" rating on shares of Alkermes in a research note on Friday, May 2nd. The Goldman Sachs Group raised their target price on shares of Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, February 14th. UBS Group reiterated a "sector perform" rating on shares of Alkermes in a research note on Monday, April 28th. Finally, Cantor Fitzgerald upgraded shares of Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.33.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.